Biocom Lifelines - Fall 2012

Fall 2012

LifeLines 4

For the Southern California Life Science Community

Cover Story: The Healthcare Tidal Wave

11 Public Policy: BIOCOM

Teams Up To Improve

California Life Science Climate

20 Guest Commentary:

Disease Foundations Back

Drug Development With

Money and Expertise 23

Purchasing Group: Introducing the The BIOCOM Travel Network

volume 21 | issue 3

THERE’S A

REASON www.sdlifesciences.com

Local innovators have trusted Cushman & Wakefield’s Life Sciences Practice Group to provide their real estate needs for the past 30 years.

It’s because we have a deep understanding of the drivers associated with scientific discovery and we have a demonstrated track record of delivering exceptional results for our clients.

That’s why year in and year out, we negotiate over 65% of all San Diego lab transactions.

Their wealth of knowledge and experience has helped us find and negotiate the best facilities at the best price. I would highly recommend C&W Life Sciences. They really get it.

Peppi Prasit,

CEO, Inception Sciences

LIFE SCIENCES TENANT REPRESENTATION

By Transaction Value Past Three Years

C&W LIFE SCIENCES JLL HUGHES MARINO CBRE CASSIDY TURLEY STUDLEY CRESA COLLIERS

(858) 452-6500

BRENT JACOBS

GREG BISCONTI

TED JACOBS

CA LICENSE NO. 791657

CA LICENSE NO. 1167920

CA LICENSE NO. 1855220

President’s

Message

by JOE PANETTA President and CEO, BIOCOM

Welcome to our fall issue of Lifelines. Much has been written and discussed in recent months about the relative standings of California and Massachusetts as life science clusters. In this issue, we focus on what distinguishes Southern California from other clusters as a premier center of innovation. In other words, how research diversity, technology convergence and collaboration strengthen life science cluster growth.

Our cover story discusses ongoing technology convergence in the healthcare industry, including cutting-edge developments in personalized diagnostics and sequencing, wireless medicine and more efficient commercial development of therapeutics. As the nation moves forward in enacting the Affordable Care Act, Southern California’s contributions will play key roles in improving the cost, delivery and availability of quality health care.

Throughout the year, we have initiated an aggressive program to work with the rapidly growing biorenewables industry. This key segment of our Southern California life science cluster is at the forefront of global innovation, developing everything from green chemistry products to advanced biofuels made from microorganisms, cellulosic crops and algae. Our work with these companies, policymakers and the investment community, is featured in an article by Jack Florio of our Capital Development Committee.

Our purchasing program now offers new travel benefits to help our members provide face-to-face service for their clients at affordable prices. BIOCOM’s robust public policy advocacy work has helped eliminate costly California Food and Drug Branch inspections that duplicate those conducted by the federal FDA. In addition, we discuss how disease foundations are backing drug development with money and expertise.

Finally, as we approach the final leg of a political season that will impact the life science industry, I’d like to mention a couple of actions BIOCOM has taken. Our Board of Directors has endorsed Rep. Brian Bilbray in his bid for reelection in the newly redrawn 52nd district. In addition, our Executive Committee has taken a position to oppose California Proposition 37, the initiative for mandatory labeling of foods produced through genetic modification. We believe this initiative provides no useful, scientifically-based information to consumers, making it completely unnecessary.

Finally, over the summer, we engaged our CEOs in a strategic planning process for BIOCOM that builds on many of the concepts and programs that you will read about in Lifelines. By developing innovative programs, we will continue to position BIOCOM to accelerate life science success.

In This Issue 4

Cover Story: The Healthcare Tidal Wave

8

BIOCOM in Action: More Than a Label

11 Public Policy Update: BIOCOM Teams Up To Improve California Life Science Climate 12 Guest Commentary: Explaining the “Bio” in Biorenewables 13 Members in Action: A Look Back at 2012 18 Membership Update: Six Reasons To Invest in a BIOCOM Membership and Tips to Maximize Your Value

25 BIOCOM Institute Update: Veterans and Women: Key Populations in our Evolving Industry 26 Premium Member Spotlights Canale Communications, Cooley LLP, Cushman & Wakefield, DLA Piper, Fisher Scientific, Merck 29 BIOCOM Board and Committees 30 BIOCOM Membership

Editor: Jennifer Landress COPY Editor: Josh Baxt LAyout: Arlene Arreola Volume 21, Issue 3 Cover Photo Illustration by JT MacMillan Photography, jt@jtmacphoto.com

www.biocom.org

C o ve r S t o r y

The HEalthcare Tidal Wave

S o u t h er n Cal if o r nia posit ion ed to take it for a g r eat r id e Everyone in our industry knows that there is a tidal wave coming in healthcare. But just how big is it?

Big. Really big.

National healthcare spending is growing faster than our economy, and has done so for each of the last four decades. I’ve seen the statistics often, but the numbers still dumbfound me. For example, in 2010 the U.S. spent $2.7 trillion on healthcare.

That’s almost $9,000 for every man woman and child in this country, more than any other country in the world spends on healthcare. That wouldn’t be so bad if we topped the charts in healthcare quality. But from an outcomes standpoint, we are ranked abysmally low—37th in a World Health Organization report

By Hei d i Chokeir , Ph.D, Canale Co m m u nicatio ns Photo by: JT MacMillan Photography

4 BIOCOM LifeLines Fall 2012

evaluating healthcare systems in 191 countries.

The disconnect between spending and outcomes can be attributed to the fact that many of the healthcare dollars we spend are wasted— as much as $750 billion a year, according to a recent report by the Institute of Medicine. Our healthcare system provides a lot of services that don’t necessarily bring good health outcomes.

This cost problem is amplified by an aging population, as 10,000 American baby boomers turn 65 every day, and will continue to do so for the next 20 years. Eighty percent of those seniors have at least one chronic disease for which they need ongoing treatment.

However, the supply of providers is not keeping pace with the increased demand. By 2015, we will be short 60,000 primary care physicians. By 2020, we will have a shortage of one million nurses in this country.

“To say that we are facing a major sustainability challenge in healthcare is an understatement,” said Joseph M. Smith, M.D., Ph.D., chief medical officer and chief science officer at

West Health, a San Diego-based organization focused on reducing healthcare costs. “We are facing a crisis of epic proportions. A tidal wave is coming.”

So there’s the bad news. Taken by itself, it’s a big, ugly reality. But even that reality is not overwhelming for the big thinkers in the life science and high tech industries in Southern California. Where others see problems, these innovators see tremendous opportunities.

Convergence of Technologies Many technologies are becoming exponentially better and exponentially cheaper. Computers are screamingly fast. Massive amounts of data can be stored cheaply and made easily accessible from just about anywhere with cloud computing. Sequencing powerhouse Life Technologies has driven the price of whole genome sequencing down by a factor of a million over the past decade.

Mobile technology has saturated our society. And excitingly, Southern California life science and high tech companies are finding ways to bring these different technologies together

to develop solutions for our healthcare woes. The convergence is happening here.

Healthcare Information Technology A number of hospital systems in Southern California are leading the nation in improving the quality of healthcare and reducing costs by getting the best information in front of doctors and nurses so they can make better decisions.

That is the goal behind electronic health records (EHR) and health information exchanges, which have been encouraged by financial incentives from the federal government and adopted by hospitals and physician practices .

Kaiser Permanente was an early EHR adopter. Last year, several Kaiser facilities in Southern California won a Stage 7 Award from the Healthcare Information and Management Systems Society for achieving the highest level of EHR implementation. Kaiser Permanente HealthConnect is the largest private-sector EHR in the world, enabling thousands of Kaiser physicians to electronically access medical records for all the organization’s nine million members.

Quick access to accurate and complete patient records, in either an inpatient or remote facility, can enhance care decision-making, reduce medical errors, improve work flow and save time. For patients, having all medical information stored in one place reduces the need to fill out redundant forms and allows them to access personal health information and communicate with providers through a secure online portal.

Implementing EHR has had its share of challenges, as adoption has not been easy for providers, who must fundamentally change how they operate.

“Whenever you bring in new technology, you need to blow up your processes because you can’t expect that your old processes are going to work with the new technology in place,” says Bill Spooner, chief information officer at Sharp Healthcare, which has also embraced EHR. “Good training programs are the key to getting through this.”

Another challenge facing healthcare systems implementing EHR is protecting patient information from accidental disclosure or hacking. In addition, caregivers must be extremely careful to confirm that the patient they are treating is indeed the patient associated with the EHR. This can be especially challenging when the the patient has a common name and arrives at the hospital unconscious. For example, there are 22,939 people named Maria Gonzalez in the U.S. Big Data Analytics Ultimately, EHRs contain a wealth of valuable data

that can be mined to reduce the cost of care and improve outcomes. While using data analytics in healthcare is still somewhat experimental, health systems are seriously considering the potential for big data to improve care and cost efficiency. Sharp Healthcare has been experimenting with analytics to review outcomes and provide feedback to physicians. Last year, San Diego-based analytics company Anvita Health was acquired by health insurer Humana, which is looking to utilize the technology to improve outcomes and reduce costs. Other health plans, such as United Health Group and Wellpoint, are developing algorithms that can predict which patients are at higher risk of developing preventable diseases, such as diabetes, so that health intervention programs can be provided.

Platforms are also being developed to identify patients who are at high risk for hospital readmissions to better coordinate post-discharge care for those patients. This simple refinement could provide big healthcare savings, as preventable hospital readmissions cost an estimated $25 billion annually in the U.S. This technology could also help hospitals avoid paying steep penalties to the federal government if their hospital readmissions rates for Medicare patients are too high.

Mobile Health Mobile devices are transforming every aspect of life, as well as creating new opportunities to address healthcare problems. Remote monitoring of patients’ biometric information using wireless devices and telemedicine might address the shortage of care providers while raising quality of care, reducing waste and improving outcomes.

“We are seeing significant opportunities in front of us because mobile as a platform is the largest technology platform in history,” said Anthony Shimkin, senior director of marketing at Qualcomm Life, a Qualcomm company dedicated to the healthcare space. “More people have access to mobile technology than running water, electricity or even toothbrushes. When you look at the possibilities in mobile healthcare, it is touching all corners of the world.”

Qualcomm Life has developed the 2net Platform and Hub, which captures biometric data from nearly any wireless medical device and securely delivers it to integrated portals or databases for storage. The 2net ecosystem is designed to overcome the challenge of connectivity and interoperability between devices from different manufacturers. Datasets from these different devices can be combined and displayed on a dashboard that monitors patients remotely.

In addition to building the 2net Platform and Hub, BIOCOM LifeLines Fall 2012

5

Qualcomm Life is using its venture capital arm, the Qualcomm Life Fund, to invest in innovative mHealth companies. For example, San Diego-based Sotera Wireless has launched the ViSi Mobile System, a platform that monitors vital signs to keep clinicians connected to their patients wherever they are. The “monitoring in motion” concept uses body-worn sensors that allow for freedom of movement while continuously monitoring and delivering vital signs. The system checks almost everything that would be monitored in an intensive care setting, such as blood pressure, heart rate, pulse, ECG, respiration rate, blood oxygen saturation and skin temperature.

The hope is that continuous mobile monitoring will detect potential health deterioration earlier, when intervention can prevent a serious adverse event that might prolong hospitalization or result in injury or even death. Precursors to adverse health events can often be seen in vital signs as early as eight hours before the event actually occurs. However, because patient vitals are not monitored continuously, these warning signs can be missed. Detecting patient deterioration early is essential to rapid response and timely intervention.

The overall impact this type of monitoring can have on health outcomes and healthcare savings is still being evaluated. Scripps Health and the Scripps Translational Science Institute recently received a $3.75 million grant from the Qualcomm Foundation to advance clinical trials to test wireless biosensor systems. The grant will also fund the development of embedded sensors to track and predict heart attacks, Type 1 diabetes and certain types of cancer.

Reducing the Disease Footprint There is a big focus on managing chronic conditions using mobile technologies, an area where huge cost savings can be realized. According to Shimkin, “Over three quarters of every healthcare dollar is spent on the treatment of chronic conditions. When you look at the prevalence of these diseases, there is an opportunity for wireless and mobile technologies to reduce the cost of care, impact how care is delivered and improve outcomes for those patients.”

San Diego-based GlySens is developing a glucose monitoring sensor that is implanted under the skin and continuously tracks blood sugar levels. The sensor transmits the glucose data wirelessly to an external display device, allowing patients to monitor and control their blood sugar levels more effectively than with occasional finger sticks.

Better blood sugar management could yield significant

6 BIOCOM LifeLines Fall 2012

healthcare savings, as diabetes and its complications are responsible for more than $117 billion in direct medical costs, according to the American Diabetes Association.

But beyond the cost savings, systems like the one GlySens is developing have the potential to dramatically improve quality of life for patients by reducing the footprint the disease places on their lives.

Smith of West Health, an investor in GlySens, notes the potential automated healthcare has to reduce the burden of chronic disease. “Imagine how overwhelming it is for a patient to manage a complex chronic disease. If you ask them to do it alone, it is too much of a burden. If we can make things unobtrusive, automatic and complianceindependent, that is a big part of the solution.”

There’s an App for That Mobile apps are another part of the solution, engaging patients and encouraging them to take better care of themselves. There are currently more than 40,000 mobile health apps that do everything from tracking what you eat or how far you walk each day to helping manage chronic conditions.

Kaiser Permanente has made its entire electronic health system available to its members via an app that runs on Android and iPhones. The app, which has been downloaded more than 95,000 times, allows Kaiser members to make appointments, check test results, order prescriptions and communicate with their care provider with the tap of a finger. Making healthcare easily accessible for patients removes many of the barriers to receiving necessary preventive care. This may improve overall patient health and reduce costly acute care spending.

Medication adherence is another way mobile apps could reduce spending and improve outcomes. Up to half of all patients do not take their medications as prescribed. It’s estimated that non-adherence contributes to 3.5 million hospitalizations and 125,000 deaths each year in the U.S., costing an estimated $290 billion in avoidable medical spending.

There are apps that address this problem, such as Care4Today Mobile Adherence, recently launched by Janssen Healthcare Innovation, Johnson & Johnson’s innovation group headquartered in La Jolla. The secure mobile app provides users with customized reminders to take medications, refill prescriptions and visit care providers. Importantly, Care4Today Mobile Adherence works on nearly any phone with web browsing capabilities, not just smart phones. This is a key to making a largescale impact in healthcare, since 91 percent of people in

the U.S. have a cell phone, but only half of those are smart phones.

“We wanted to create something that had the potential to help everyone, not just the fraction of the population that have a smart phone,” said Diego Miralles, M.D., head, Janssen Healthcare Innovation. “This will be critical to expanding the platform into integrated care and management of chronic conditions.”

Modernizing Clinical Trials Virtually every life science entrepreneur in the region would agree that the cost and time it takes to develop a drug just isn’t sustainable. If we are serious about reducing healthcare spending, we can’t continue conducting clinical trials in the same ways we have for the past 30 years. There are many places where emerging technologies have the potential to significantly reduce the cost and time it takes to develop a drug, as well as make better drugs.

EHR can be used to identify potential clinical trial participants. Genetic screening can select patients most likely to respond to a drug, or eliminate those who are predisposed to adverse events, lessening the potential for costly late-stage drug failures. Wireless sensors can monitor patient vital signs and replace antiquated paper diaries with mobile interfaces. Giving trial participants the ability to log daily entries describing symptoms and side effects would create a far more accurate profile of a drug and its efficacy.

“Implementing these technologies in clinical trials will result in much more detailed and reliable information about drugs and devices,” says Joe Panetta, president and CEO of BIOCOM. “This could transform the process, creating a future win for pharma and biotech because the FDA is going to embrace this increased transparency.”

Catch the Wave Southern California is uniquely positioned to become THE region to transform the healthcare industry. Undeniably, San Diego is the wireless healthcare capital of the world. The numbers are amazing. The region has more than 3,000 wireless companies and more than 1,700 life science companies, including biotech, medical device, diagnostics and pharma companies, as well as research institutions.

DNA sequencing powerhouses, such as Life Technologies, call San Diego home. High quality hospital systems that are leading the way in implementing new technologies are also here. Some of the world’s top biomedical research institutes are just walking distance from one another on the Torrey Pines mesa. There is venture capital funding in both the life science and high tech sectors. Southern California has everything it needs to be the engine for healthcare innovation—solving some of healthcare’s most challenging problems. We can catch this tidal wave and take it for a great ride.

“Southern California has such a diversity of people, ideas, companies and technologies being developed that can’t be replicated anywhere,” said Shimkin, when asked about the potential of the region in this era of new high-tech medicine. “The number of Nobel Laureates, the types of companies, the presence of genomics expertise….When you open that up to the types of things we can work on together, the opportunities are impressive.”

February 27-28, 2013 The Lodge at Torrey Pines www.biocom.org

BIO C OM i n A c t i o n

More Than a Label

by Joe Panetta, President and CEO, BIOCOM Sometimes seemingly wellintentioned regulation can result in more harm than good. Such is the case with Proposition 37, the California genetically modified food labeling initiative. Proponents of Proposition 37 contend that its goal is to educate consumers about what is in their food, so they can make intelligent choices about what they eat. That’s an excellent goal, but one that Proposition 37 can’t possibly accomplish. To make intelligent choices about foods produced by genetically modified crops, consumers need to educate themselves about what genetic modification means, and that cannot be addressed with just a few words in fine print on a food package. So, before consumers decide how to vote on Proposition 37, I’d like to answer the common questions that can’t be addressed on food labels.

What are genetically modified foods?

A genetically modified food is made from a crop or animal whose genetic characteristics have been slightly changed. We have been influencing the genetic makeup of plants and animals to create better crops and livestock for hundreds of years using selective breeding techniques. Today, genetically modified plants are produced using targeted methods of modification, such as the introduction of a gene that has a specific useful characteristic. The most common genetic modifications are disease, herbicide or pest resistance, drought tolerance or prolonged freshness.

How is genetic modification beneficial?

Genetically modified crops were 8 BIOCOM LifeLines Fall 2012

approved by the U.S. government 17 years ago. An example of one such crop is corn that produces a protein that is harmless to humans and livestock, but makes the corn resistant to certain insects. This makes it possible to increase corn production using fewer pesticides. This is good for consumers and growers because it reduces the need for pesticides, and it is better for the environment.

Herbicide resistant crops allow growers to reduce weeds in fields using products that are less persistent in soil. Crops can be modified for drought tolerance to allow production in arid regions, conserving precious water resources. Other genetically modified fruits and vegetables stay fresh longer or have higher nutrient content. Some genetically modified plants are helping to rescue crops from diseases in parts of the world stricken by famine and poor growing conditions. Overall, direct genetic modification has worked alongside traditional breeding to enable more efficient food production, lowering food prices and feeding more people in a more sustainable way.

Is food made through genetic modification safe?

Genetically modified crops have been studied by government agencies, researchers and the agriculture industry globally for more than 25 years with no detected adverse effects.

In the U.S. these crops are evaluated by several federal agencies, such as the Food and Drug Administration, the Department of Agriculture and the Environmental Protection Agency. These agencies have concluded that unless a genetically

modified crop differs significantly from its traditional counterpart, there is no reason to label that product, because such labeling would provide no useful information. The same is true of crops produced through traditional breeding techniques. Since genetically modified crops were first introduced in 1995, the majority of doctors, scientists and health experts have concluded that these foods are safe and require no special notice to consumers.

Will changing California food labeling laws as outlined in Proposition 37 help or hurt consumers?

The answer to that question is at the heart of whether or not one should support Proposition 37. Proposition 37 won’t help consumers. In fact it might result in a disservice in the long run for several reasons. Consumers need more than a misleading label to be educated about what is in their food. Additionally, in an environment of economic uncertainty, proposition 37 will increase the cost of groceries for the average family by an estimated $350-400 per year. Proposition 37 will introduce even more red tape for California farmers and grocers, placing them in danger of frivolous lawsuits through a “bounty hunter” clause in the initiative. These are many unintended negative consequences caused by a label that falls short of its goal of educating consumers about what is in their food.

This Opinion piece was written in advance of the November elections; we wanted to share with BIOCOM members one of the actions we had taken in relation to this ballot measure.

Introducing

Torrey Ridge SCIENCE CENTER San Diego’s premier Life Science campus

CLASS “A” LAB SPACE AVAILABLE FOR LEASE ±339,445 Square Feet (Divisible)  Three, 2-story Class A laboratory buildings over subterranean parking

Contacts

 Pharmaceutical quality, existing building infrastructure

Rich Danesi Lic. 01869864 858 546 4652 richard.danesi@cbre.com

 Modern exterior and interior improvements  Ability to accommodate users from 15,000 SF up to 339,445 SF  LEED Certified  Campus environment with excellent on-site amenities including: → Fitness Center → Café → Walking/jogging trails → Outdoor dining and seating areas  Prominent building top and monument signage available  Outstanding canyon views  Direct access to I-5, UCSD, La Jolla and Del Mar

Ryan Egli Lic. 01445615 858 546 4648 ryan.egli@cbre.com CBRE 4365 Executive Drive, Ste. 1600 San Diego, CA 92121 www.cbre.com Charles McClure Lic. 01445615 949 863 0388 cmcclure@legacypartners.com

Life Science Properties | Brokerage Services

CREATING CREATING ENVIRONMENTS ENVIRONMENTS

THAT THAT INSPIRE INSPIRE

BioMed BioMedRealty Realtyisiscreating creatingmodern modernenvironments environmentsthat thatinspire inspire innovation and culture of collaboration to meet the needs innovation and culture of collaboration to meet the needsofof today’s today’slife lifescience sciencecompanies. companies.The Thenewly newlydelivered deliveredCoast9 Coast9 campus in the heart of Sorrento Valley, offers modern facades, campus in the heart of Sorrento Valley, offers modern facades, several severalmove-in-ready move-in-readyspec specsuites, suites,and andamenity amenitycenter center complete with hot café, fitness center, collaboration lounge, complete with hot café, fitness center, collaboration lounge, bike bikeracks racksand andwelcome welcomecenter. center. www.biomedrealty.com www.biomedrealty.com 858.207.5931 858.207.5931

P u b l i c P o l i cy Up d a t e

BIOCOM Teams Up To Improve California Life Science Climate

by Jimmy Jackson, Vice President of Public Policy, BIOCOM

I recently celebrated my s e v e n t h anniversary serving our members at BIOCOM. One issue that has been raised often during these years is duplicative regulation at the state and federal levels. I am happy to report that, thanks to efforts by Assemblyman Jerry Hill (D-San Mateo), bill cosponsors BIOCOM, BayBio and CHI and our many member companies, Governor Jerry Brown recently signed Assembly Bill (AB)1277 into law.

This legislation addresses facility inspections by state regulators, which largely duplicate similar inspections by the U.S. Food and Drug Administration (FDA). AB 1277 eliminates many of these state facility inspections. The bill will require the Food and Drug Branch (FDB) of the California Department of Public Health to accept the certification and findings of the FDA in most cases, rather than requiring a separate state facility inspection, as is current practice. The legislation preserves the FDB’s mission to inspect a business if there is reason to believe public health may be at risk, or if the FDA has

requested assistance.

“These state facility inspections provide little in the way of protecting and preserving public health, but they cost companies millions of dollars in lost productivity to accommodate the inspections,” said Joe Panetta, President and CEO of BIOCOM. “Governor Brown has challenged business to bring him ways government can be more efficient, and we are thankful Assemblyman Hill and Governor Brown took action when potential solutions were presented to them.”

On the federal level, user fee reauthorizations for prescription drugs, medical devices and biologics were passed as part of the Food and Drug Administration Safety and Innovation Act (FDASIA). The Act seeks to expand the FDA’s use of an accelerated approval process. In addition, FDASIA enhances transparency, predictable performance goals and fosters early, more regular communication between the industry and reviewers during the regulatory process.

The bill includes crucial requirements that govern antibiotics development, help speed the de novo process and should expedite therapy advancement for patients suffering from serious and life-threatening

diseases.

Rep. Brian Bilbray (R-San Diego) was particularly helpful in championing the breakthrough therapies and de novo designations in the legislation. The breakthrough therapies provision is particularly important, as it creates a new designation to expedite the ability of biotech and pharmaceutical companies to develop targeted drugs that show promise for serious or lifethreatening conditions.

BIOCOM continues to enhance our relationship with FDA leadership.

During a recent Washington visit, Joe Panetta met with several senior FDA staff members, including Deputy Commissioner Steven Speilberg. We continue to explore new ways to be an effective conduit between our members and the agency.

Finally, I want to say a public and heartfelt thank you to BIOCOM’s associate director of Federal Affairs for the past four years, Madeleine Baudoin. Madeleine has taken her talents to new challenges, but was integral in the development of our increased federal efforts over the past four years. We are grateful for Madeline’s efforts and wish her success in her new endeavor.

BIOCOM LifeLines Fall 2012

11

GU E ST C OMM E NT A R Y

Explaining the “Bio” in Biorenewables

by Jack Florio, President, Capital Development Committee and Partner, Eckel & Partners People often ask: What are b i o re n e w a b l e s are and why is B I O C O M supporting them?

The simple answer is that biorenewables has at is core the combination of two disciplines which are central areas of expertise to the biotech industry – biological sciences and chemistry. These disciplines with the use of catalysts, chemical or microbial, turn plant products into high value products like chemicals and fuels. Therefore the definition of White Biotechnology fits squarely into the biorenewables space.

• White biotechnology works to improve an industrial process.

Examples include engineering an organism to produce a specific chemical, a flavor or fragrance and to produce, or accelerate a more efficient chemical reaction You will also hear terms like Green Biotechnology, which is closer to the definition of biorenewables and Red Biotechnology which is really something different • Green biotechnology, not surprisingly, involves plants. This means finding innovative ways to grow hardy crops in stressful environments, increasing yields, producing disease-resistant plant or crops with internal, natural pesticides and using algae or crops to produce biofuels.

• Red biotechnology seeks to improve medical care. For example, organisms can be genetically 12 BIOCOM LifeLines Fall 2012

engineered to produce a specific drug, such as an antibiotic or insulin.

As you can see, BIOCOM’s support for biorenewables is a natural fit.

Biorenewable processes use some of the same chemistry as well as many of the same organisms and cell-based techniques that drive traditional biotechs. In fact, many of the companies in this space are spinoffs or outgrowths from traditional biotech startups. Although there is a unique group of VC’s investing only in this sector, many of the larger VC’s have branched out and followed the evolution of the industry with a focused group of biorenewables partners. In addition, this industry is also the subject of federal policy discussions around tax incentives, job creation, green energy production and chemistry – initiatives that align perfectly with BIOCOM’s public policy agenda.

From a financing standpoint, this industry faces many of the same challenges traditional biotech companies must overcome – technology uncertainties, development risk and long time lines. Other challenges include greater capital needs for scale up, a different set of regulatory measures and global competition for government subsidies.

Many of these scale factors generate a strong need for large company partnerships.

Following a series of very successful Life Science VC days, the BIOCOM Capital Development Committee has scheduled their first Biorenewables VC Day on November 14. Participants can meet with Thomas Huot, PhD,

Managing Director of Vantage Point Capital Partners and Dr. Daniela Proske, principal, BASF Venture Capital America. Dr. Proske has a Ph.D. in biochemistry and worked in both the life science and chemical industries before becoming a venture capitalist focused on biorenewables.

“BASF has more than three decades of experience in white biotechnology.

They use biotechnological methods to manufacture vitamins, enzymes, pharmaceutical intermediates and specialties for personal care, food and feed industries. The rapid progress in genetic engineering and genome science has opened up biosynthesis routes which have been considered impossible until recently. Startup companies in the biorenewable space have developed promising platform technologies to address the need for new bio based chemicals” says Proske.

“The symbioses between emerging companies with strategic partners like BASF and its corporate Venture arm BASF Venture Capital, America can accelerate the path from innovation to manufacturing & commercialization of bio based chemicals.”

In addition, for 2013, we are also exploring a partnering day for biorenewables.

The Capital Formation Committee is looking forward to a successful program on November 14. Companies interested in participating in the BIOCOM biorenewables programs should contact Jennifer Landress at jlandress@biocom.org.

Members in Action > A Look back at 2012

Partnering Conference 2012: Melinda Richter, Prescience International, Teri Melese, School of Medicine, UCSF and Paul Laikind, Sanford Burnham Research Institute

PAC Legislators and Candidates Reception: Don Fitzgerald of Genentech, Scott Peters, Candidate for Congress, Keith Wilson of Takeda California, and Assemblyman Nathan Fletcher

2013

June 12-14, 2013 San Diego Convention Center FDA Roundtable: Jim Plante of Pathway Genomics, Bhaskar Shetty of Pfizer, FDA Deputy Commissioner Stephen Spielberg, and Joe Panetta of BIOCOM

PARTNERING MEETINGS

KEYNOTE ADDRESSES

EXHIBITION HALL

BREAKOUT SESSIONS

NETWORKING

RECEPTIONS

PLENARY SESSIONS

Members in Action > A Look back at 2012

BIOCOM Golf Tournament: Golfers warming up for a beautiful day and a great event at Santaluz

Medical Device Expo: Ichor Medical Systems won two prestigious awards at BIOCOM’s Med Device Expo: The “Far Out” and “People’s Choice” awards.

HR Conference: Kris Dunn, Chief Human Resources Officer, Kinetix

14 BIOCOM LifeLines Fall 2012

FDA Roundtable: Jimmy Jackson of BIOCOM, FDA Commissioner Margaret Hamburg, George Strait of the FDA, Keith Wilson of Takeda California, and Kevin Larkin of TherOx

BIOCOM’s PAC Legislative Staff Appreciation Happy Hour: Nancy Noe of Johnson & Johnson, Amber Starbuck of SDGE, and Christi Knight of the Office of Supervisor Bill Horn

October Breakfast Meeting: Jim Schaeffer of Merck Research Labs,William Brody of The Salk Institute, Michael Marletta of The Scripps Research Institute and John Reed of Sanford-Burnham Medical Research Institute

BSKB-BIOCOM-LifeLines-Ad.indd 1

4/20/12 1:18 PM Client: Birch, Stewart, Kolasch & Birch, LLP (BSKB) ae: Jeff Lupisella x225

ContaCt: Elizabeth Richards, riche@bskb.com, 703.205.8000

PM: Jeff Lupisella x225

VeR. : 1/2 pg. hor bleed

PRojeCt: BSKB-063 ‘12 BIOCOM LifeLines Ad

Mod. date: 04.20.12 Fri 1:17 PM

Run date: Spring 2012

Pub: LifeLines/BIOCOM

January: Travel

4CP: n n n n

Size: 8.75” x 5.25”

Confidential: Information contained within this document is only intended for the recipient. Copying, distribution or communication of this document is stricly prohibited.

13221 Woodland Park Rd., Suite 420, Herndon, VA 20171

AER Travel Enterprise Holdings Park Hyatt Aviara

tel 703.437.8018

American Corporate Manchester Grand Hyatt Sedan & Limousine vizual.com Hyatt Irvine Grande Colonial

fax 703.437.8268

Hyatt La Jolla

February: Information & Data Mission 3 AIS

The BIOCOM Purchasing Group Supplier Event Series is a new program designed to bring together suppliers and members with common interests for a casual networking experience.

These events will take place outside of the office in unique spaces and will feature different market segments each month.

We’ve heard your feedback, value your time and want to help maximize your savings by providing you with this opportunity to learn more about your BIOCOM Purchasing Group Suppliers.

Mentara Elsevier

PR Newswire

March: Office Office Depot Tech Depot

Canteen Sharp Business Systems

Pure Water Technologies

May: Facilities Veolia Source One Shred San Diego

Pegasus Building Services Prudential Building Services

June: HR RetirementDNA Barney & Barney

Innovative Lease Services Chubb

Monitor Liability Managers Employee Perks Providers

RAISING THE BAR

Introducing the NEW

The Lodge at Torrey Pines

Hilton Hotel ¼ Mile

Torrey Pines Golf Course

NORTH TORREY PINES ROAD 11025

11077

11085

11011

3030

Shared conference center

For More Information Please Contact:

Cafe

JED STIRNKORB Lic. 00888859 858 546 4640 jed.stirnkorb@cbre.com

Outdoor seating with wifi access

RICHARD DANESI Lic. 01869864 858 546 4652 richard.danesi@cbre.com

Fitness Center

RYAN EGLI Lic. 01445615 858 546 4648 ryan.egli@cbre.com

CBRE 4365 Executive D 858 546 4600 ww.cbre.com/sand

Torrey Pines Science Park NEW 20,000 SF Lab Suite (Move-in Ready) NEW Fitness Center NEW Cafe NEW Conference Center

TORREY PINES ROAD 11149

3020

Pond, waterfall & outdoor seating with wifi access

Dr., Ste. 1600

diego

M E MB E RSHIp Up d a t e

Six Reasons To Invest in a BIOCOM Membership and Tips to Maximize Your Value

by Michelle Wright, Manager of Membership, BIOCOM 1. SAVE MONEY BIOCOM’s Purchasing Group negotiates significant, volume-based savings and favorable terms on products and services frequently used in the life science industry. With 35 vetted contracts, members receive substantial bottom-line savings. We saved members over $39 million in 2011. Members can easily save more than they pay in annual membership dues and frequently recover their initial investment within the first quarter.

Tips to maximize your savings: • Make an appointment with BIOCOM’S Purchasing Group • Review your Quarterly Savings Report. Are there suppliers you’re not using?

• Take advantage of Employee Perks: Access personal discounts at 150+ local establishments FUN FACT: BIOCOM members with 11-25 employees save on average 21 times their membership dues.

2. GOVERNMENT ADVOCACY ON YOUR BEHALF We provide members with government advocacy at the local, state and federal levels. We consider potential new legislation, monitor and weigh-in on proposed legislation and regulations and communicate positions taken by the organization’s membership to regulatory bodies and elected leaders.

18 BIOCOM LifeLines Fall 2012

Tips to maximize your advocacy: • Contact our Public Policy department to discuss your company’s issues and interests • Join the Facilities, EH&S, FDA or Legislative committee • Attend Public Policy events 3. INCREASED VISIBILITY FOR YOUR COMPANY Ensure your company is wellrecognized throughout Southern California’s life science community.

Tips to maximize your company’s visibility: • Upgrade to a Premium Membership • Reach 15,000 people – just submit news about your company to our e-newsletter, the Biocommunique • Post your events on our Member Events Calendar • Use our conference rooms • Update your company information in the online directory • Be part of our Member-toMember Program: Offer a discount on your products/services to other Members • Sponsor an event 4. NETWORKING OPPORTUNITIES Expand your network through 75 events.

Tips to maximize peer-to-peer interaction: • Participate in 15 committees: CRO, Education, EH&S, Facilities, IP, Medical Device, Reimbursement, etc.

• Attend events (discount rate for Members) • Connect with members via our events and Membership Directory

5. MEET WITH CAPITAL DEVELOPMENT INVESTORS BIOCOM aggressively attracts investors from around the globe to invest in Southern California’s vibrant life science ecosystem.

Tips to maximize your access to capital: • Join the Capital Development Committee • Apply to participate in our Partnering Conference, VC Days, Pharma Days and/or Pitchers’ Club (for industry companies) • Attend events relative to the capital formation process (NIH & SBIR grant process, CFO roundtables, Investor Roundtables, and more) 6.WORKFORCE TRAINING AND DEVELOPMENT The BIOCOM Institute serves as the bridge between learning institutions and life science companies to build comprehensive education initiatives that advance science literacy and ensure a productive future for the industry workforce.

Tips to maximize advancing your prosperous workforce: •Take advantage of cutting-edge learning through BioCollaborative, an e-learning platform • Join the BIOCOM Institute, Education or Scholarship Committee • Receive reduced pricing for job postings on our Career Center We are here to help you succeed.

To learn more please contact me at 858.455.0300 x116 or mwright@ biocom.org

http://www.americanis.net

SEARCH

COMPANY We Rock

CLOUD Virtualize

SERVICES For You

WHY AIS? Read On

San Diego Best Data Center

CONTACT Do It!

Let AIS Be Your Data Center

Reliable, Secure Solutions to Transform CAPEX into OPEX

From cloud, security, and network services to disaster recovery and colocation, AIS provides reliable, secure, enterprise-class data center solutions in San Diego and Phoenix.

SERVICE

EXPERTISE

SUPPORT

Why Buy IT Gear? From cloud,

People Matter. With over 150 years

Compliance Counts. Hosting

security, and network services to

of cumulative IT services experience

hundreds since 1989, AIS upholds

disaster recovery and colocation, AIS

across the senior leadership team,

the highest levels of SSAE 16

makes it easy for clients to get what

AIS knows what it takes to deliver

professionalism in each of our SOC

they need without CAPEX.

superior client satisfaction.

1, 2, 3-audited data centers.

www.americanis.net

866.971.2656 phone

sales@americanis.net BIOCOM LifeLines Fall 2012

19

GU E ST C OMM E NT A R Y

Disease Foundations Back Drug Development With Money and Expertise

by Mandy Jackson, West Coast Editor, SCRIP Intelligence Funding basic research remains a priority for d i s e a s e foundations.

H o w e v e r, n o n p r o f i t organizations are increasingly making business-savvy investments in commercial drug development for patients and families that donate in hopes of finding a cure, or at least a disease-modifying therapy.

Executives whose companies have applied for funding say foundations are just as rigorous at vetting potential investments as venture capital groups, maybe more so. Foundations have scientific connections and massive research catalogues to help them gauge whether a business pitch is full of promise or running on empty hope.

Venture philanthropy by patient groups can be the icing on a manylayered cake. But the foundations’ most precious resource may be their access to key opinion leaders as well as their abilities to reach willing clinical trial participants and advocate passionately for patients. In addition, a nonprofit’s endorsement adds credibility that may sweeten the deal for potential for-profit investors and partners.

Only about two to three percent of pharmaceutical research and development funding comes from disease foundations. But money is not the only contribution patient groups can make to drug companies developing much-needed medicines.

“If a patient group really wants to pursue this, they can leverage a lot of 20 BIOCOM LifeLines Fall 2012

change with relatively few dollars,” says Kristin Schneeman, a program director at Washington, D.C.-based FasterCures, which helps connect government, foundations, companies and investors.

For example, several foundations have established registries to inform patients about clinical trials. These registries alert patients to potential new treatments and speed up patient enrollment in drug trials. Some fund biomarker studies to identify new drug targets.

Isis Pharmaceuticals, based in Carlsbad, California, works with several foundations representing patients with rare diseases or unmet medical needs, such as the Spinal Muscular Atrophy (SMA) Foundation.

Isis did not receive financing from the SMA Foundation to fund its antisense drug ISIS-SMNRx, now in Phase I development with Biogen Idec.

However, the nonprofit is funding studies on the history of SMA and disease biomarkers. SMA gave Isis an early look at the data to advance the company’s drug development.

“It’s been a tremendous benefit working with them,” said Isis senior vice president of research Frank Bennett. “Their strategy has been to lower the barriers so that we can justify going forward.”

Fast Forward, the foundation established five years ago by the National Multiple Sclerosis Society to fund drug and diagnostic development, has also been working to lower barriers and accelerate drug development. Fast Forward president Timothy Coetzee said the organization is a facilitator that helps

connect companies with useful research and development resources.

The goal is to keep the research moving forward. Even when the group rejects a proposal, it tells the company how it can develop the project further or where else it might find funding.

The Epilepsy Therapy Project (ETP) and the Epilepsy Foundation recently announced they will merge into one group under the Epilepsy Foundation banner to maximize their resources.

They will raise funds to support investments in smaller companies alongside venture capital firms or corporate partners, encourage more patients to participate in clinical trials and educate the industry about the benefits of epilepsy drug development.

According to ETP chairman and co-founder Warren Lammert, epilepsy can be a gateway to other indications for new drugs. In addition, epilepsy clinical trials fail less frequently than those for other neurological disorders. “There is an economic opportunity here that can be exploited,” said Lammert.

While drug development may be about medical need, the industry is driven by money. This revenue funds research and provides profits to repay investors who gambled that new medicines will find their way to the patients who desperately need them.

For more biopharma news, analysis and data from SCRIP Intelligence, visit www.scripintelligence.com.

Life Sciences Group

lOOKing fOr new laB Space?

Check out San Diego’s Premier life Sciences Real Estate Team Available lab space from 2,000 Sf to 200,000 Sf

www.sdlabspace.com

coming Soon SunriSe at tOrrey pineS

Connecting World-Class Lab Space with World-Class Life Science Dave Odmark 858.546.5430

dave.odmark@cassidyturley.com

Jerry Keeney

858.546.5489

jerry.keeney@cassidyturley.com

Brian Starck

858.546.5486

brian.starck@cassidyturley.com

Project Leasing / Tenant Representation / Capital Markets / Project & Development Services / Property Management / Corporate Services

Greener Reusable Mop Protocol

Why purchase mop heads and dispose them when you can reuse them?

Introducing Our Newest Validated Reusable Mop Offering Biotechnology & Pharmaceutical Applications

HYDRAL Mop ™

Validated Sterile Reusable Microfiber Mop System

Our HYDRAL™ Mop is a densely constructed, multi-layered, sealed edge polyester microfiber mop manufactured with a higher filament count for extra softness and particulate removal.

- Superior absorbency and strength - Provides an ultra-clean wiping material for critical applications -

Special stitching provides longevity and added cleanliness Inert to chemicals and bacteria Retains contaminants during mopping and released when laundered Fast drying

- Surface cleaning of doors, walls and ceilings

Reduce carbon footprint Reduce waste Reduced costs >30% Improve compliance

visit us @ www.prudentialuniforms.com

Premier Supplier in the

Purchasing Group

Member of

Cleanroom Contact: Patrick Bihn, PCS/ BioCom Account Executive PartickB@pos-clean.com 213.364.0848

P u r c h a s i n g g r o u p Up d a t e

Introducing the BIOCOM Travel Network

by Rick Fultz, Managing Director, BIOCOM Purchasing Group Good things come to those who wait. For m e m b e r companies, who have relied on the BIOCOM Purchasing Group to bring them unmatched savings and value added services for fifteen years, the wait for a comprehensive discount travel program is over. Since its official rollout in October, the BIOCOM Travel Network has redefined the way members conduct business. Featuring discounts at five regional hotels in San Diego and Orange County, a best-inclass sedan service, car rentals through Enterprise/National (whose fleet is larger than all major competitors combined) and a top-rated travel agency based in La Jolla, the BIOCOM Travel Network has already become a critical travel planning component for companies throughout the region.

While video conferencing and other communications technologies play important roles, nothing can fully replace the power of face time to build sound business relationships. We created the Travel Network in response to our members’ ongoing need to maximize the benefits of business travel, while minimizing the cost. The Network is designed specifically to provide the travel solutions you need to grow your business at affordable prices.

For more than a year, we have

negotiated with travel vendors throughout the region to provide our members abundant choices and superior service. And we’re not done yet. We have carefully researched which regions our members visit most and are now identifying excellent hotels to add to the Network and negotiating discounted domestic and international air travel with multiple airlines.

Help us Help You Bringing in the big discounts from a giant rental car company was no cake walk. At times, negotiations were fierce. Making a good air travel deal for our members will be even tougher.

To succeed, we must aggregate travel data from BIOCOM member companies to determine how much potential air travel is at stake. Initial research suggests our members spend more than $100 million each year on air travel. But that’s just an estimate, and we need some hard data from our members to back it up.

If you would like BIOCOM to negotiate substantial airline discounts for you and your colleagues, there are two ways to help. First, work closely with our travel team to help us determine what you’ve spent recently on air travel. Second, book your travel through our discounted travel agency, AER Travel. The agency can anonymously pool total air travel spending to create models for the airlines.

If you would like to help, please contact any BIOCOM purchasing staff. We will be glad to walk you

through the process. Backed by our association’s collective efforts, we will be able to negotiate significant airline discounts to help you go farther on your travel dollar.

Membership has its Privileges The best part about this travel program is the benefits are not limited to corporate use. As a BIOCOM member, you can take advantage of these programs for your personal travel needs through our Employees Perks Program. Through the program, you can capitalize on deep discounts on Enterprise or National car rentals, save big through AER Travel’s association with the Virtuoso Network and get great room rates at the Grande Colonial, Hyatt Regency Irvine, Grand Hyatt San Diego, Hyatt Regency La Jolla and the Park Hyatt Aviara for yourself, business clients, friends or family.

Over the years, we have received tremendous feedback about our BIOCOM Purchasing Group services. However, the BIOCOM Travel Network may be the best perk yet. Because it can be used for either business or personal travel, the Travel Network can benefit every BIOCOM member. And, with your help, the scope of these services will only get bigger.

Whether you’re booking a room, renting a car or planning a trip, visit www.biocom.org/purchasing_group/ travel today to book, save and relax.

We’ve got you covered.

BIOCOM LifeLines Fall 2012

23

E V E NTS Up d a t e February 27-28, 2013 The Lodge at Torrey Pines

by Shaye Exner, Director of Conferemces & Corporate Sponsorships, BIOCOM The Annual BIOCOM Global Life Sciences Partnering Conference attracts more than 200 highlevel licensing and b u s i n e s s development executives, as well as CEOs and life science-focused members of the venture community.

The two-day conference, which will be held in San Diego on February 26-28 at The Lodge at Torrey Pines, is attracting top deal makers from the world’s largest biopharmaceutical companies, including the chief licensing officer at Merck, the vice president of strategic transactions at BMS and the heads of business development at GlaxoSmithKline, Novartis and Biogen Idec. In addition, attendees have access to managing directors at the region’s top VC firms, including venBIO, TPG Biotechnology, Venrock, Sofinnova and Frazier Healthcare. There will be panel discussions, presentations by young biotechs, opportunities for one-on-one meetings and various networking events throughout the conference.

2013 BIOCOM Global Partnering Conference Speakers • Karen Bernstein, Chairman & Editor-in-Chief, BioCentury • Marty Birkhofer, Vice President of Strategic Transactions Group, Bristol-Myers Squibb • Richard Brudnick, Vice President of Business 24 BIOCOM LifeLines Fall 2012

Development, Biogen Idec Dan Burgess, President & CEO, Rempex Pharmaceuticals • Iain Dukes, Vice President, External Research and Development, Amgen • David Kabakoff, Executive in Residence, Sofinnova • Brian McVeigh, Vice President, WWBD Transactions and Investment Management, GlaxoSmithKline Pharmaceuticals • Carole Nuechterlein, Head, Roche Venture Fund • Heather Preston, Managing Partner, TPG Biotechnology • Bill Rastetter, Partner, Venrock • John Reed, CEO, SanfordBurnham Medical Research Institute • Tony Rosenberg, Head of Global BD & Licensing, Novartis • James Topper, General Partner, Frazier Healthcare • Kurt Von Emster, Managing Director, venBio LLC • Mark Wiggins, Senior Vice President, Business Development, Elcelyx • Rob Wills, Vice President, Alliance Management, Johnson & Johnson • Barbara Yanni, Vice President and Chief Licensing Officer, Merck We are also recruiting participants who are interested in one of the coveted company presentation slots during the conference. Presentations are 15 •

minutes, with a 5 minute changeover.

In addition, there will be opportunities (30 minutes or longer) for companies to conduct private meetings with major pharma representatives for more in-depth discussions. All registrants are eligible to participate in the one-on-one meetings.

Companies interested in a presentation slot can submit an application for review. Details on how to submit an application can be found at http://www.biocom.org/event/ Partnering_Conf_2013/ This is going to be an exciting conference. I encourage you and your colleagues to attend.

Is this conference right for you?

Who will be there: • Large and Small Pharmaceutical and Biotechnology Companies • Senior Level Business Development Professionals • Licensing Executives • CEOs • VCs If your company would like to support this unique conference, limited sponsorship opportunities are available. This is your chance to become part of the most prestigious life science event in Southern California. For more information contact Shaye Exner at shaye.exner@biocom.org

BIO C OM INSTITUT E Up d a t e

Veterans and Women: Key Populations in our Evolving Industry

by Kristie Grover, Executive Director, BIOCOM Institute The life sciences are one of the fastest growing sectors in the California e c o n o m y.

However, as t o d a y ’ s bioscience industry grows, veterans and women are often underrepresented. The BIOCOM Institute recognizes that these groups represent a promising talent pool to build the life science work force. With this in mind, the Institute and technology partner ZBglobal are collaborating to help increase their numbers in the industry.

Early on, the BIOCOM Institute and ZBglobal pledged to provide free BioCollaborative tuitions for veterans and active duty military. I witnessed firsthand how hard work and good training can lead to a successful career.

My father, an Army sergeant, used the GI Bill to earn undergraduate and graduate degrees and begin a long successful career in the life science industry. Starting as an intern, he rose to become a director in pharma, president of a medical device company and a venture capitalist for some of the nation’s largest funds.

This is what happens when you combine good people and good education.

We want to make similar opportunities available for the men

and women who served in Iraq and Afghanistan. Marine Lance Corporal Kevin Blanchard was on patrol in Iraq when an improvised explosive device detonated and he lost his left leg. After participating in the AdvaMed Medical Technology Veterans Program (MVP) Boot Camp for Returning Heroes, Blanchard was encouraged to pursue a career in the life sciences. In particular, he expressed his interest in working in the prosthetics industry, allowing him to help fellow amputees. His passion and transferable skills will make him a great asset.

Women face their own unique barriers when trying to succeed in the life science industry. Recently, I attended the Society for Industrial Microbiology and Biotechnology Annual Meeting. Strangely, I kept being directed to a ballroom dance competition rather than the life science event. While I can see the humor in the situation, this type of gender stereotyping is common for women in our industry.

Regardless of the situation, we need to find creative ways to encourage and support women in the life sciences. The BIOCOM Institute is partnering with Women in Bio (WIB) to narrow this gender gap by working together to help women enter and thrive in this sector. Specifically, The BIOCOM Institute and WIB actively support entrepreneurship and career

growth for women in the biosciences.

Veterans need help transitioning from military to civilian life. Women need female role models to encourage them to overcome gender bias and move up the corporate ladder. The Institute and ZB are partnering with the community to help find mentors and establish corporate programs that support veterans and women.

Together, we can and will make a difference.

If you are interested in a program to hire veterans, support professional development for women in the life sciences or would like to mentor an individual, please contact Ashley Reynolds areynolds@biocom.org or 858-455-0300 x129.

BIOCOM LifeLines Fall 2012

25

Premium Member sPOTLIGHTS

•

•

Canale Communications is a public relations and investor relations agency 100% focused on building reputation equity for life science companies.

Reputation equity gives companies the credibility to raise capital, the authority to respond to a crisis and the ability to navigate the volatile life sciences marketplace.

The senior team at Canale Communications works closely with client teams and has provided public and investor relations strategy to more than 150 life science companies of all shapes and sizes.

•

Named “Law Firm of the Year” in Biotechnology by US News – Best Lawyers in 2011, the first year the category was awarded

•

Ranked #1 in Life Sciences by Chambers USA: America’s Leading Lawyers for Business in 2007, 2008, 2009, 2010 and 2011

•

www.canalecomm.com

•

•

•

DLA Piper is a leading provider of legal services to biotechnology and pharmaceutical companies based in the US and around the world.

Our life sciences lawyers include former industry professionals, many of whom have PhDs and advanced degrees in the life sciences and medical fields.

With 4,200 lawyers in 77 offices in 31 countries, DLA Piper has the comprehensive services platform and market presence to meet the needs of any type or size of life sciences client.

www.dlapiper.com

26 BIOCOM LifeLines Fall 2012

Consistently rank #1 in the BioPharm Insight Biotechnology and Pharmaceutical Licensing League Table Report for 2010 and 2011

•

For over 25 years, the Cushman & Wakefield Life Sciences Group has been the leader in representing life science tenants, regularly negotiating over 65% of all San Diego laboratory lease transactions.

•

Oldest, most experienced real estate team dedicated solely to the life sciences industry.

•

Oldest, most established brokerage company in San Diego (since 1891).

•

Co-founders and a board member of BIOCOM.

www.cooley.com

•

Fisher Scientific, part of Thermo Fisher Scientific, was founded in 1902

•

Over 50 professionals in the San Diego and Southern California region to support your life science research, safety, healthcare and science education needs

•

Offer extensive and complete portfolio of services to support laboratory equipment, production and chemicals

•

Our premier service brands: Doe&Ingalls, Fisher Bioservices, Fisher Clinical Services, Global Chemicals, Fisher Financial Services and Unity Lab Services

www.fishersci.com

www.sdlifesciences.com

•

In 1891, George Merck began to establish roots in the United States and set up Merck & Co., Inc. in New York.

•

106,000 employees worldwide

•

Ticker MRK

•

Since 1987, Merck has donated 2.5 billion tablets of MECTIZAN® (ivermectin) in more than 30 countries worldwide, helping bring River blindness disease closer to elimination.

www.MERCK.com

THANK

YOU

As BIOCOM approaches our 18 year anniversary, we are proud to honor and recognize our long-term members celebrating milestone anniversaries with us. These companies are commemorating fifteen-plus years of loyal membership. BIOCOM greatly appreciates these committed members who’ve helped ensure the life sciences industry remains a strong and vibrant sector of the region’s community and economy. Thank you!

www.biocom.org

VWR

Accelerating Life Science Solutions in California

GLOBAL REACH, LOCAL SUPPORT. SINCE 1852.

VWR is a global leader in the distribution of laboratory products, supplies and services, offering the best product choices, including the Exclusive VWR Collection, from premier manufacturers to customers around the globe. We are committed to providing efficient, effective solutions for all your Life Science needs by offering products, service and support that make your work faster, easier and more accurate.

Board of directors and Committee Leadership 2012 B i o c o m B o a r d o f D ir e c t o r s Board Officers and Executive Committee: CHAIR: David Webb, Ph.D., Celgene * VICE CHAIR: Stephen Ferruolo, J.D., Ph.D., USD School of Law * CHAIR ELECT: Magda Marquet, Ph.D., Althea Technologies * VICE PRESIDENT AND GENERAL COUNSEL: Lisa Haile, Ph.D., DLA Piper * VICE PRESIDENT – FINANCE: Daniel Kleeburg, Ernst & Young * VICE PRESIDENT AND SECRETARY: Carin Canale-Theakston, Canale Communications* VICE PRESIDENT – INDUSTRY: Theodore Schroeder, Cadence Pharmaceuticals, Inc.* PRESIDENT & CEO: Joe Panetta, BIOCOM * Vince Anido, Ph.D. Scott Biel, Mintz, Levin, Cohn, Ferris, Glovsky & Popeo Martin Birkhofer, M.D., Bristol-Myers Squibb Michael Brown, Stradling Yocca Carlson & Rauth Terrence J. Bruggeman, BioTork, LLC Daniel Burgess, Rempex Pharmaceuticals John M. Dunn Geoffrey S. Eich, Amgen M. Wainwright Fishburn, Jr., Cooley LLP * Don Fitzgerald, Genentech Jack Florio Scott Foote, Square 1 Bank Alan Gold, BioMed Realty Trust Jeffrey W. Guise, Ph.D., Wilson, Sonsini, Goodrich & Rosati Jason Hannon, NuVasive Jim Hinrichs, CareFusion Matthew Hudes, Deloitte LLP Scott Huennekens, Volcano Corporation Guy J. Iannuzzi, 321 Medical Launch Brent D. Jacobs, Cushman & Wakefield David Kabakoff, Ph.D., Sofinnova Ventures Michael Kamdar Richard Kaufman, Foley & Lardner Kevin Larkin, TherOx Harry Leonhardt, Amylin Pharmaceuticals Jack Lief, Arena Pharmaceuticals, Inc. * Jacob Levin, Ph.D., UC Irvine Steven Mento, Ph.D., Conatus Pharmaceuticals, Inc. * William Molloie, PwC Paul Negulescu, Ph.D., Vertex Pharmaceuticals, Inc. Tina Nova, Ph.D., Genoptix, Inc. A Novartis Company John Parrish, BioVascular, Inc. John C. Reed, M.D., Ph.D., Sanford-Burnham Medical Research Institute Trindl Reeves, Barney & Barney LLC * Herm Rosenman Theodore D. Roth, Roth Capital Partners LLC Scott Salka James Schaeffer, Ph.D., Merck Research Laboratories* Christophe Schilling, Ph.D., Genomatica, Inc.* Timothy Scott, Pharmatek Laboratories, Inc. Bhasker Shetty, Ph.D.,Pfizer La Jolla Larry Stambaugh, Centre for Bioinspiration, SD Zoo Global* Mark Stevenson, Life Technologies * Scott N. Wolfe, Latham & Watkins Randall E. Woods, Sophiris Bio* Kleanthis Xanthopoulos, Ph.D., Regulus Therapeutics

BIOCOM Board Members-Ex-Officio: Ruben Barrales, San Diego Regional Chamber of Commerce David Brenner, M.D., UCSD School of Medicine Mark Cafferty, San Diego Regional Economic Development Corporation Constance Carroll, Ph.D., San Diego Community College District Gary Friedman, The Agouron Institute Peter Preuss, The Preuss Foundation Robert Sullivan, Ph.D., Rady School of Management, UC San Diego

Bi ocom C ommi ttees Capital Development Committee* Carin Canale-Theakston, Canale Communications David Kabakoff, Ph.D., Sofinnova Ventures CRO Committee Timothy Scott, Pharmatek Laboratories, Inc. Education Committee Mike Greig, Pfizer La Jolla Ashley Wildrick, San Diego Workforce Partnership Environmental, Health and Safety Committee Cliff Hanna Dan Shiel, Pfizer La Jolla Facilities Committee Andy Darragh, Ferguson Pape Baldwin Architects Brent D. Jacobs, Cushman & Wakefield FDA Committee Magda Marquet, Ph.D., Althea Technologies Michele Yelmene, Merck Intellectual Property and Patent Law Committee Margaret Dunbar, Sanford-Burnham Medical Research Institute Daniel Hart, Knobbe Martens Olson & Bear LLP Legislative Committee Richard Ledford Jori Tulkki, Hologic Gen-Probe, Inc. Medical Device Committee Noel Gillespie, Procopio, Cory, Hargreaves& Savitch Joleen Schultz, 321 Medical Launch Public Policy Oversight Committee* Larry Stambaugh, Centre for Bioinspiration, SD Zoo Global Paul Laikind, ViaCyte Purchasing Board Committee* Jack Lief, Arena Pharmaceuticals, Inc. Reimbursement and Market Access Committee Michael Pollock, Reynolds Pollock & Associates Scholarship Committee Bente Hansen, BenteHansen and Associates Connie Matsui BIOCOM Institute Board Committee* Steven J. Mento, Ph.D., Conatus Pharmaceuticals, Inc. *Board level committee

LIFE DIRECTOR: Kennon W. Baldwin, Ferguson Pape Baldwin Architects * David Hale, Somaxon Pharmaceuticals * Duane J. Roth, CONNECT *Executive Committee Members

BIOCOM LifeLines Fall 2012

29

BIOCOM MEMBERSHIP Pr e mi u m 321 Medical Launch Alexandria Real Estate Equities AIS (American Internet Services) Amylin Pharmaceuticals Arena Pharmaceuticals Bayer Healthcare* BioMed Realty Trust BioSpace Booz Allen Hamilton BP Biofuels Bristol-Myers Squibb California Manufacturing Technology Consulting Canale Communications Celgene Conatus Pharmaceuticals Cooley Covington & Burling Cushman & Wakefield Deloitte DLA Piper Eli Lilly Ernst & Young Ferring Research Institute Fisher Scientific* Foley & Lardner Genoptix Gen-Probe Goodwin Procter ISTA Pharmaceuticals KPBS Latham & Watkins Life Technologies Merck Research Laboratories of San Diego Merrill Corporation Mintz, Levin, Cohn, Ferris, Glovsky & Popeo NuVasive Pfizer Global R&D La Jolla PwC VWR International Wilson Sonsini Goodrich & Rosati

Biotec h n o l o g y Abbiotec Abgent Abide Therapeutics ACADIA Pharmaceuticals Accugent Laboratories ActivX Biosciences Advanced Biomatrix Advanced Targeting Systems ADVENTRX Pharmaceuticals Agradis Aires Pharmaceuticals AM Chemicals Ambit Biosciences AMBRX American Peptide Company Amgen Amicrobe

Amplyx Pharmaceuticals AnaptysBio AndroScience Applied Proteomics Aragon Pharmaceuticals Ardea Biosciences Arrayomics Astellas Pharma US* aTyr Pharma Avantgen Aviva Biosciences Bachem Americas BioAtla Biocept BioLegend Biomatrica Biomyx BioNano Genomics Bionomics

30 BIOCOM LifeLines Fall 2012

BioTork Bruin Biometrics Cadence Pharmaceuticals CalAsia Pharmaceuticals CalciMedica Cardinal Specialty Cellana Cell Applications Ceregene Cibus Coda Therapeutics CovX Research Crucell Biologics Custopharm Cylene Pharmaceuticals eFFECTOR Therapeutics* ELISA Link* Dart Neuroscience DSM Food Specialties* Elcelyx Therapeutics Electronic BioSciences Elevation Pharmaceuticals Epeius Biotechnologies Expression Drug Designs Fabrus Fate Therapeutics Genelux Corporation Gene Therapy Systems Genentech Genomatica GenWay Biotech GlaxoSmithKline Global Bio Therapeutics USA GWR Instruments Halozyme Therapeutics Histogen Hitachi Chemical Research Center Huya Bioscience International ICX Biosystems iGentBio* Inception Sciences Inhibrx InnoPep* Innovative Cell Technologies* Integrated DNA Technologies Intercept Pharmaceuticals* International Stem Cell Intrepid Therapeutics* Intrinsic LifeSciences InvivoGen InVivoScribe Technologies ISIS Pharmaceuticals Jaleva Pharmaceuticals Johnson & Johnson Pharmaceutical Research & Development Kyowa Hakko Kirin California La Jolla Biologics La Jolla Pharmaceutical Company Ligand Pharmaceuticals Lilly Biotechnology Center Lithera Lpath Lumena Pharmaceuticals* MabVax Therapeutics MEI Pharma Meritage Pharma Monsanto Nautilus Environmental

NeuroGenetic Pharmaceuticals* Nitto Denko Technical Novartis Pharmaceuticals NovaRx Noven Pharmaceuticals Novo Nordisk* Nucelis Ocera Therapeutics Octagon Research Solutions Optimer Pharmaceuticals Optimum Therapeutics Orexigen Therapeutics Otonomy Pacira Pharmaceuticals Pathway Genomics Pfenex Phage Pharmaceuticals Pharma Form Polaris Group Polynoma* PolyPeptide Laboratories Predictive Biology PrimaPharm PrimeGen Biotech Prometheus Laboratories ProSci Incorporated QED Bioscience Receptos Regulus Therapeutics Rempex Pharmaceuticals Renova Therapeutics Ribomed Biotechnologies RuiYi SAFC Pharma Sangart Sanguine BioSciences* Sanofi-Aventis R&D Santarus Senju USA Senomyx Sequenom SG Biofuels Sherpa Clinical Packaging Sirenas Marine Discovery* Somaxon Pharmaceuticals Sophiris Bio* Sorrento Therapeutics Stemedica Cell Technologies Stemgent Synthetic Genomics Takeda San Diego Tanabe Research Laboratories Tocagen Tracon Pharmaceuticals Tragara Pharmaceuticals Trius Therapeutics Vala Sciences Vasgene Therapeutics Vaxiion Therapeutics Verdezyne Verenium Vertex Pharmaceuticals Vet-Stem ViaCyte Vical Virapur Wellspring Biosciences* Wildcat Discovery Technologies Zacharon Pharmaceuticals Zogenix Zyagen

Medical Device & Diagnostic Accumetrics Acon Laboratories* Aethlon Medical Alphatec Spine Althea Technologies Astute Medical Banyan Biomarkers BeneChill BioDx Biological Dynamics bioTheranostics Breathe Technologies CareFusion CeloNova Biosciences Cliniqa CRISI Medical* Critical Diagnostics CTK Biotech CVAC Systems Cytori Therapeutics DermTech International DexCom Diagnostic Consulting Network Ellipse Technologies* Enigma Diagnostics Entra Health Systems Epic Sciences Epitope Diagnostics Fallbrook Engineering FemCap* Fortimedix USA Freedom Meditech Glaukos Corporation* Glysens Ichor Medical Systems IGNYTA, Inc. INOVA Diagnostics Inovio Biomedical Interplex Medical* Interventional Spine Invetech InVision Biomedical Group Ionian Technologies Iris Personalized Medicine Ivantis* KFx Medical MARDX Diagnostics Medipacs Micell Technologies NanoImaging Services Naviscan NeoMend OncoSec Medical Organovo PhotoThera PLUS Diagnostics* Preventice Qualigen Quantum Design Quidel ResMed REVA Medical ReVision Optics* Ridge Diagnostics Roka Bioscience* SD Biosensor USA* Shire Regenerative Medicine Sirigen

SpectraScience Suneva Medical Tandem Diabetes Targeson Tensys Medical* TherOx Tristan Technologies TrovaGene Valor Medical Vantagepoint Laboratory Partners VertiFlex Vertos Medical Volcano Yulex

CRO Absorption Systems Accelagen Accelovance Acurian Advantar Laboratories Agility Clinical Althea Technologies AMRI AnaBios Annova Chem Apricus Biosciences Aptuit Behavioral Pharma Bend Research Biologics Process Development BioStorage Technologies* BioTox Sciences* Cato Research Celula ChemDiv Concortis Biosystems Davos Chemical EastHorn Clinical Services Epistem* eStudySite Exon BioSystems Explora BioLabs Hamari Chemical Hungaro Trial CRO Huntingdon Life Sciences Integrium Clinical Research* IriSys JadeBio KMC Systems MedinCell MicroConstants Millenium Laboratories Molecular Response Neox USA NeurAccel Biosciences NexMed (U.S.A.) Novella Clinical Pacific World Discovery PacificGMP Pharmatek Laboratories Prescos Profil Institute for Clinical Research PSI CRO Puracyp Quadrants Scientific RetroVirox Robarts Clinical Trials* RxRs CRO*

Synteract Theorem Clinical Research* Tioga Research Toxikon Triligent International Ultimate Labs Verum* Velesco Pharmaceutical Services Zenobia Therapeutics

Key P r ov i d e r Airgas Barney & Barney Harlan Laboratories KPMG Oracle Procopio,Cory, Hargreaves & Savitch Qualcomm San Diego Gas & Electric

P r ov i d e r 22nd Century Ventures* 2Connect 360 Vantage Accelrys* Advantar Laboratories AMN Healthcare AppFolio* Assay Depot* Avantor Performance Materials Beckloff Associates Bente Hansen & Associates Bingham McCutchen BioSurplus Biotech Primer BioTix Birch, Stewart, Kolasch & Birch Brinson Patrick Securities Caliber Associates Campbell Alliance Capsugel, Americas Region CB Richard Ellis China Business Partners Chubb Group of Insurance Companies Clarkston Consulting Clinigen Pharma Cymer Degenkolb Engineers Domain Associates Dudnyk* EBD Group Enterey Fabiani & Company Ferguson Pape Baldwin Architects Fish & Richardson P.C. Fitzpatrick, Cella, Harper & Scinto Forward Ventures Global BioPharm Executive Search Good & Roberts, Inc. General Contractors Grande Colonial Grant Thornton HCP Life Science Estate The Health Ed Group* Hooper, Lundy & Bookman

Hughes Marino Hyatt Regency La Jolla at Aventine Innovative Lease Services InVenios Irving Group Jackson & Blanc HVAC Contractors* Kelly Scientific Resources Kilroy Realty Knobbe, Martens, Olson & Bear Kronos Leadership Edge McKenna Long & Aldridge Medpoint Mentara Michael Ehrenfeld Company Morgan, Lewis & Bockius Morrison & Foerster Moss Adams NOVA Biologics Occupational Services Office Depot OmniComm Systems Oxford Finance Pegasus Cleanroom Services Phillips Plastics Corporation Prevost Construction PR Newswire Project Management Advisors Prudential Cleanroom Services Q5 Group QuakeHOLD! Industrial Relocation Coordinates Retirement DNA Roth Capital Partners Russo Partners Sanford Rose Associates Sartorius Scisive Consulting ShareVault Sharp Business Systems Sheppard Mullin Richter & Hampton Shred San Diego Silicon Valley Bank SLM Contract Furniture Smart Source Snell & Wilmer Sofinnova Ventures Sonceboz Square 1 Bank Stradling Yocca Carlson & Rauth Studley Sughrue Mion PLLC Sullivan United Moving & Storage Technical Safety Services The Business Cleaning Company The Sandler Group Thomas, Mcnerney & Partners The Irving Group United Parcel Service (UPS) Veolia Versant Ventures Wells Fargo Insurance Services Witt Kieffer Your Bio Team

Non-P rofi t American Cancer Society, Border Sierra Region CA Institute for Regenerative Medicine Calibr* California State University, San Marcos City of Murrieta City of Temecula Combined Health Agencies CONNECT Consulate of Canada Human BioMolecular Research Institute Institute of Engineering in Medicine ISM San Diego J. Craig Venter Institute La Jolla Bioengineering Institute La Jolla Infectious Disease Institute La Jolla Institute for Allergy & Immunology Lawrence Family Jewish Community Center MiraCosta College Biotech Program Mt. San Jacinto College National University PhRMA Point Loma Nazarene University PRISM Rady School of Management, UCSD Salk Institute for Biological Studies, The San Diego Clinical Translational Research Institute, UCSD San Diego Community College District San Diego Convention & Visitors Bureau San Diego Regional Chamber of Commerce San Diego Regional Economic Development Corp.

San Diego Natural History Museum San Diego Workforce Partnership San Diego World Trade Center San Diego Zoo Global Sanford-Burnham Medical Research Institute Scripps Health Scripps Research Institute, The Scottish Development International SDSU, CSUPERB Program Swedish American Chamber of Commerce San Diego The BioIndustry Association Torrey Pines Institute for Molecular Studies UCI, Office of Research UCSD, Department of Bioengineering UCSD External Relations Office UC San Diego Extension UCSD School of Medicine

UCSD, Technology Transfer Office University of San Diego Vaccine Research Institute of San Diego

Indi vi dual Antoinette Azevedo Bernard King Elliot Parks Gary Friedman Julie Ames Michael Pollock Nicholas Maczkov Peter Preuss Richard Ledford Walter J. Bochenko

* New Members from May to October 2012

BIOCOM LifeLines Fall 2012

31

Prsrt Std U.S. Postage PAID Permit #2325 San Diego, CA

4510 Executive Drive, Plaza One San Diego, CA 92121-3021 858.455.0300 www.biocom.org Please send a change of address or subscription request to Katelyn Doyle at kdoyle@biocom.org.

Step Into the Future of Life Sciences — We Are Already There

• • • • • • •

ADMET Process Biostatistics Biotechnology Manufacturing Biotechnology Project Management Business of Biotech Clinical Trials Diagnostics

• • • • • •

Drug Discovery and Development Genomics Life Sciences IT Medicinal Chemistry Quality Assurance and Control Regulatory Affairs

(858) 534-9353 | unexbio@ucsd.edu | extension.ucsd.edu/lifesciences

SP11-4057

UC San Diego Extension’s Life Sciences department offers a broad array of courses and certificate programs to meet the continuing education needs of the Life Sciences community. The programs support high-level skill development for industry professionals and career transition for those interested in entering the field.